References
- van Vollenhoven R. F., Klareskog L. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry. Arthritis Rheum 2003; 48: 1500–3
- van Vollenhoven R. F., Ernestam S., Harju A., Bratt J., Klareskog L. Etanercept versus etanercept plus methotrexate: a registry‐based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003; 5: R347–51
- Zink A., Listing J., Kary S., Ramlau P., Stoyanova‐Scholz M., Babinsky K., et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005; 64: 1274–9
- Geborek P., Crnkic M., Petersson I. F., Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow‐up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793–8
- Hetland M. L., Unkerskov J., Ravn T., Friis M., Tarp U., Andersen L. S., et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scand J Rheumatol 2005; 34: 40–4
- American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328–46
- Feltelius N., Fored C. M., Blomqvist P., Bertilsson L., Geborek P., Jacobsson L. T., et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005; 64: 246–52